P roteins are frequently modified by diverse enzymes such as kinases, methyltransferases, ubiquitinylases, and acetyltransferases. Such modifications are called post-translational modifications, and the relevance of post-translational modifications to both cellular function and human diseases has been highlighted. Among those modifications, phosphorylation is well known as a critical process for enzymatic activity, 1 signal transduction by recruiting complexes, 2 DNA binding, 3 and cell division. 4 Although biological roles of other modifications, especially acetylation, have not been intensively studied yet, the function of acetylation is as important as that of phosphorylation. 5 For example, it is well established that lysine acetylation of histone 3 or 4 at the promoter region of certain genes is associated with transcriptional activation of downstream genes. Acetylation of lysine causes a loosening of the nucleosome by neutralizing the positive charge. 6 p53, one of the most recognized oncoproteins, requires acetylation for stabilization, which thereby results in the subsequent activation for its own
functions. 7 Interestingly, a single molecule may be subject to multiple post-translational modifications; in addition, one modification often affects other types of modifications. 8 Mammalian histone deacetylases (HDACs) are divided into 4 classes. Class I HDACs are ubiquitously expressed, whereas class II HDACs show tissue-specific expression. Class III HDACs require NAD + for their activity and are associated with longevity. 9 HDACs remove acetyl groups from an ε-amino-terminal lysine on histone 3 or 4. 6 HDACs are so named because of this HDAC activity; however, many groups have reported that nonhistone proteins can also be deacetylated by HDACs. Such nonhistone proteins include p53 by HDAC1 in cancer physiology, 10 glucocorticoid receptor by HDAC2 in chronic obstructive pulmonary diseases, 11 v-rel reticuloendotheliosis viral oncogene homolog A by HDAC3 in silencing mediator of retinoic acid and thyroid hormone receptor/nuclear receptor corepressor 1 complex formation, 12 GATA1 by HDAC3/HDAC4/HDAC5 in murine erythroleukemia cell differentiation, 13 α-tubulin by HDAC6 in control of cell motility, 14 and pleiomorphic adenoma gene 1/2 by HDAC7 in tumorigenesis. 15 Thus, to date, HDACs are also called lysine deacetylases to describe their function rather than their targets. 16 We and others have studied the functional importance of HDACs in cardiac hypertrophy. We have demonstrated that HDAC2 provokes cardiac hypertrophy 17, 18 and that phosphorylation-dependent activation of HDAC2 19 plays a critical role in the regulation of antihypertrophic genes. 20 By contrast, Hdac5 and Hdac9, which are class IIa HDACs, are reported to inhibit cardiac hypertrophy as demonstrated by their knockout in mice in which hypertrophic phenotypes were exaggerated in response to hypertrophic stresses. 21, 22 Moreover, a variety of prohypertrophic agonists, including inotropic agents, induce cytoplasmic redistribution of class IIa HDACs, whereas cardiac hypertrophy is prevented when class IIa HDACs are tethered in the nucleus. 23 Although those 2 classes of HDACs have opposite roles, both classes are still involved in the single disease of cardiac hypertrophy, which strongly suggests interconnections between them. In this study, we investigated the crosstalk between HDAC2 and class IIa HDACs in the development of cardiac hypertrophy. Here we suggest a novel mechanism of regulation of HDAC2 activity in the development of cardiac hypertrophy. We propose that p300/CBP-associated factor (pCAF) acetylases HDAC2, whereas HDAC5, a class IIa HDAC, directly removes the acetyl moiety from HDAC2. We show that HDAC2 is a prohypertrophic mediator suppressed by class IIa HDACs through acetylation dynamics.
Methods

Neonatal Rat Ventricular Cardiomyocyte Culture
All animal experiments were performed after approval by the Chonnam National University Medical School Research Institutional Animal Care and Use Committee. Neonatal rat ventricular cardiomyocytes (NRVCs) were prepared as described previously. 19 
Primary Culture of Adult Rat Ventricular Cardiomyocytes
Adult rat ventricular cardiomyocytes (ARVCs) were cultured from adult Sprague-Dawley rat hearts according to a previous report 24 with slight modifications. Twelve-week-old male rats were used (Daehan Biolink, Daejeon, Korea).
Cardiac Hypertrophy Model
Eight-week-old adult male CD1 mice were purchased (Daehan Biolink) and housed in individual plastic cages. Mice were anesthetized with 2,2,2-tribromoethanol (300 mg/kg; intraperitoneally), and osmotic pumps (Alzet; Durect Corp, Cupertino, CA) were inserted as described previously. 19 
HDAC Activity
HDAC activity was assessed by the use of a commercially available kit (HDAC Fluorometric Assay/Drug Discovery kit; Enzo Life Sciences, Inc, Plymouth Meeting, PA).
Trichostatin A Pulse
To minimize the unwanted effect by remnant inhibitors, the medium was replaced after incubation overnight. Then, NRVCs were incubated with inhibitor-free medium for 4 hours more after extensive washing with inhibitor-free PBS.
Cell Size Measurement
Immunocytochemistry was performed as previously reported. 19 ARVCs were infected with adenovirus overnight and exposed to reagent-containing media for 24 hours more. Both sarcomeric actinin and GFP-positive cells were used for cell size measurement.
[ 3 H]Leucine Incorporation Assay
After either transfection with plasmid for 6 hours (NRVCs) or infection with adenovirus overnight (ARVCs), the medium was changed to 1.0 μCi/mL [ 3 H]leucine-containing medium overnight. Tritiated leucine incorporation was measured as described previously. 19 
In Vivo Delivery of Adenovirus
Adult male C57BL/6 mice (Daehan Biolink) or Hdac5-null mice were prepared for in vivo delivery of adenovirus at 8 weeks of age. The day after insertion of the osmotic pump, 1×10 11 ifu Ad-GFP or Ad-Hdac2 K75R virus was injected via the tail vein.
Statistical Analysis
One-way ANOVA was used to test significances between >3 groups, which was followed by the Tukey multiple comparison post hoc test. When the variances of each group were not equal by the Levene test, the Dunnett T3 test was used for a post hoc test. Statistical analysis was performed with PASW Statistics 20 (SPSS, an IBM Company, Chicago, IL).
All reagents and detailed methods are described in the Online Data Supplement.
Results
HDAC2 Acetylation in the Development of Cardiac Hypertrophy
Previously, we reported that the activation of HDAC2 induced by phosphorylation of S394 is critical in the development of cardiac hypertrophy. 19 in cardiac hypertrophy. We first examined the acetylation status of HDAC2 to hypertrophic stresses. NRVCs were exposed to endothelin-1 or phenylephrine overnight. Cellular extracts were immunoprecipitated by antiacetyl lysine antibody and probed with anti-Hdac2 antisera. Hdac2 acetylation was significantly increased by phenylephrine ( Figure 1A ) and endothelin-1 ( Figure 1B) . The results of densitometer analysis were shown in the Online Table. We also examined the acetylation status in vivo in an animal model. An increase in the acetylation of Hdac2 in response to either isoproterenol ( Figure 1C ) or pressure overload ( Figure 1D ) was also observed in the mouse heart. Next, we examined the effects of modulators of acetylation. Interestingly, acetylation of Hdac2 was dramatically decreased by garcinol, a histone acetyltransferase inhibitor (Figure 1E , second lane). We also examined whether the inhibition of HDAC could induce hyperacetylation of the Hdac2 molecule itself. We treated NRVCs with trichostatin A (TSA) for 8 hours and then washed out TSA. This TSA pulse significantly increased Hdac2 acetylation ( Figure 1E , right lane), which further suggested that Hdac2 is a target of acetylation by histone acetyltransferase or other HDACs.
To elucidate whether acetylation of Hdac2 is related to its enzymatic activity, we tested the intrinsic activity of Hdac2 after treatment with garcinol or TSA. We first treated Hdac2 immunoprecipitates with TSA and measured the activity without washing out the TSA. This resulted in the complete inhibition of Hdac2 enzymatic activity (data not shown), which resulted from a direct inhibition of Hdac2 by the remaining TSA in the precipitates. Thus, we altered the experimental procedures to examine the activity after induction of acetylation of Hdac2, that is, TSA pulse. Hyperacetylation of Hdac2 by TSA was not decreased after washing out (Online Figure I ). According to this preliminary experiment, we measured intrinsic HDAC2 activity after cleaning up TSA. Some chemical inhibitors that have recently been developed show relative selectivity on 1 class of HDACs; for example, apicidin 25 and SK 7041 17 preferentially inhibit class I HDACs. Thus, we examined which class of HDAC mediates deacetylation of Hdac2 by using specific class I HDAC inhibitors or nonselective HDAC inhibitor. TSA pulse dramatically induced Hdac2 activation, whereas apicidin pulse failed to do so ( Figure 1F ).These results implied that deacetylation is mediated by class IIa HDACs.
HDAC2 K75 Residue as an Acetylation Target
We next examined which residue is responsible for acetylation of HDAC2 by using 2 truncated mutants of Hdac2: the N-terminal part (Hdac2-N; amino acids 1-260) and the C-terminal part (Hdac2-C; amino acids 250-488). The acetylation band was detected only in Hdac2-N (Online Figure II) .
Hdac2-N contains 18 lysine residues, and the bioinformatics database indicated that both K75 and K90 could be a target for acetylation (http://www.uniprot.org/; http:// www.phosphosite.org/). Thus, we made acetylation-resistant mutants by use of a single-point mutagenesis technique in which K75 or K90 was substituted with arginine. After transfection of those mammalian expression vectors, an immunoprecipitation-based acetylation assay was performed. Acetylation of Hdac2 was not detected when lysine 75 was substituted by arginine (Hdac2 K75R; third lane in the second panel in Figure 2A ); however, we did not see any changes with K90R (fourth lane in Figure 2A ). Furthermore, TSA-dependent hyperacetylation of Hdac2 was not observed in Hdac2 K75R ( Figure 2B ), which strongly suggested that K75 was specific for acetylation. Figure 1 . HDAC2 is acetylated in the development of cardiac hypertrophy. To study endogenous Hdac2 acetylation in response to hypertrophic stresses, 2 mg of protein was immunoprecipitated with 2 μg antiacetyl lysine antibody, and acetylation of Hdac2 was visualized by antisera against Hdac2. Two percentage of input was used for showing loading controls. Hdac2 acetylation was significantly upregulated by either 100 μmol/L phenylephrine (PE; A) or 10 nmol/L endothelin-1 (ET-1; B) in the primary cultured neonatal rat ventricular cardiomyocytes. Hdac2 hyperacetylation was also detected in hearts obtained either from mice treated with continuous infusion of isoproterenol (ISP; C) or mice that underwent pressure overload (D). E, Hdac2 acetylation was decreased by garcinol, a histone acetyltransferase inhibitor, but was increased by trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor. F, Deacetylase activity of Hdac2 was downregulated by garcinol but induced by pan-HDAC inhibitor. Apicidin, a specific class I HDAC inhibitor, did not affect HDAC2 activity. Results are shown as mean±SE. **P<0.01; NS, not significant. AoB indicates aortic banding; IB, immunoblot; and IP, immunoprecipitation. March 28, 2014
The relationship between K75 acetylation and HDAC2 enzymatic activity was further examined by comparing the intrinsic activities of Hdac2 wild-type and K75R. The deacetylation activity was halved in K75R mutant ( Figure 2C ). We next examined whether acetylation of Hdac2 K75 is required for the development of cardiac hypertrophic phenotypes. We transfected mammalian expression vectors of either wild-type or K75R Hdac2 and performed a promoter assay with hypertrophic marker genes. Hdac2 K75R failed to induce promoter activation of natriuretic peptide precursor A (Nppa), a gene encoding atrial natriuretic factor ( Figure 2D ). To confirm this further, NRVCs transfected with either wild-type or K75R Hdac2 were stimulated by phenylephrine, and the promoter assay was performed. Wild-type Hdac2 increased Nppa promoter activity (first and third columns in Figure 2E ) as we reported previously, 19, 26 and the increase in activity was further potentiated by phenylephrine (third and fourth columns in Figure 2E ). The activation induced by Hdac2 K75R was very weak compared with that by wild type in the basal condition (third and fifth column in Figure 2E ). Interestingly, forced expression of Hdac2 K75R significantly blunted the phenylephrine-derived hypertrophy response (fourth and sixth columns in Figure 2E ), which suggests that HDAC2 K75R works in a dominant-negative fashion in phenylephrine-treated NRVCs. A similar result was obtained when myosin heavy chain-7 promoter (Myh7, encoding β-myosin heavy chain) was used for the promoter assay (Online Figure III) . The protein amounts were the same in our experimental conditions (Online Figure  IV) . The measurement of protein synthesis, a hallmark of cardiac hypertrophic phenotypes, 27 Figure 2G ), and phenylephrine-induced increase in cell size was potentiated by wild-type Hdac2 (second and fourth columns in Figure 2G ). As in Figure 2E and 2F, the infection of Hdac2 K75R mutant successfully blocked the prohypertrophic feature of α-adrenergic agonist. However, like wild-type Hdac2, both K75R and K75Q were still localized in the nucleus (Online Figure VI) . Thus, we concluded that Hdac2 K75 is an acetylation target that mediates hypertrophic phenotypes in cardiomyocytes.
Effect of Acetylation on HDAC2 Phosphorylation
Some residues that are susceptible to post-translational modification in Hdac2 have been reported to modulate the intrinsic deacetylation activity of HDAC2; S394, S422, and S424 are phosphorylation sites responsible for activation, 28 whereas H141 forms a critical component for a deacetylase pocket. 29 In addition, S-nitrosylation of C262 and C274 also affects the enzymatic activity by an unknown mechanism. 30 We previously reported that casein kinase 2α1 (CK2α1)-mediated phosphorylation of Hdac2 S394 is mandatory for the activation and plays an important role in the development of cardiac hypertrophy. 19 In this report, we found that acetylation is also important for activity. Thus, we investigated the mechanism by which acetylation affects the intrinsic activity of Hdac2. Because of their functional similarities, we first assumed that an interplay may exist between the 2 post-translational modifications of acetylation and phosphorylation. Thus, we checked the phosphorylation status of Hdac2 K75R. In the basal condition, S394 phosphorylation was significantly decreased in K75R ( Figure 3A) . By contrast, no difference in acetylation status was seen between wild-type Hdac2 and S394A mutant ( Figure 3B ). In addition, hyperacetylation in either basal or TSA-provoked condition was also observed in diverse Hdac2 mutants such as phosphorylation-dead mutants of Hdac2 S394A, S394/422/424A, or even an enzyme-dead mutant of H141A (Online Figure VII) , which further suggests that those modifications of phosphorylation do not affect acetylation, whereas acetylation influences phosphorylation. Next, S394 phosphorylation was measured after TSA pulse. Hdac2 K75R was not phosphorylated by TSA, whereas wild type was significantly increased ( Figure 3D ). As observed above, the deacetylase activity in wild-type Hdac2 was further increased by TSA pulse (second and third columns in Figure 3E ). However, the potentiation effect was completely absent when K75R was used (fourth and fifth columns in Figure 3E) . Surprisingly, although acetylation was increased by TSA among the mutants tested, except for K75R, TSA-mediated Hdac2 activation was detected only in wild-type Hdac2 ( Figure 3F ).
We further investigated the net effect of acetylation and phosphorylation by use of a double mutant that contains both acetyl-mimicking (K75Q) and phosphor-dead (S394A) mutations. The acetylation mimic mutant of Hdac2, Hdac2 K75Q, showed prohypertrophic features both in HDAC activity (Online Figure VIII ) and in [ 3 H]leucine incorporation assay ( Figure 3G) ; however, acetylation-associated hypertrophy was not observed in the Hdac2 K75Q/S394A double mutant. To check the alteration of phosphorylation of different sites by acetylation, we performed an immunoprecipitation-based phosphorylation assay with Hdac2 S394A and Hdac2 K75R/ S394A. Phosphorylation at the residues other than S394 was not changed by acetylation (Online Figure IXA) . Likewise, the intrinsic activity of Hdac2 K75R/S394A was not further decreased when compared with that of Hdac2 S394A (Online Figure IXB) , which suggests that basal phosphorylation was not affected by acetylation.
We further questioned how K75 acetylation regulates S394 phosphorylation; we tested whether acetylation is required for the interaction with CK2α1 that phosphorylates S394. 19 The acetylation-resistant mutant failed to interact with CK2α1, which implicates that K75 acetylation is indispensable for the interaction with CK2α1 for phosphorylation (Online Figure X) . These results emphasized that acetylation precedes phosphorylation, but phosphorylation is required for the acetylation-mediated development of hypertrophic phenotypes.
Hdac2 Acetylation by pCAF
Next, we questioned which histone acetyltransferase can induce acetylation of HDAC2. Because garcinol is effective for inhibiting acetylation of Hdac2 ( Figure 1E ) and that garcinol is an inhibitor of both p300 and pCAF, 31 we checked their interaction with HDAC2 and the functional relevance of acetylation. Among the histone acetyltransferases tested, pCAF physically interacted with Hdac2 ( Figure 4A-4C ). Moreover, Hdac2 acetylation was increased by transfection of pCAF in a dose-dependent manner ( Figure 4D ). Interestingly, we could find no significant interaction between Hdac2 and p300 (Online Figure XIA) . In addition, p300 was not involved in Hdac2 acetylation (Online Figure XIB) , which agrees with the result of a previous report. 32
Hdac2 Deacetylation by Hdac5
As suggested by the results shown in Figure 1E , we assumed that one of class II HDACs may work to remove acetylation of Hdac2. First, we checked the physical interaction between Hdac2 and class II HDACs. In our experimental model, among those tested, Hdac5 (Figure 4E and 4F) and Hdac9 (Online Figure XIIA and XIIB) were successfully coimmunoprecipitated by Hdac2.
Both HDAC5 and HDAC9 are well-known antihypertrophic mediators. 21 Thus, we examined whether either HDAC5 or HDAC9 could deacetylase HDAC2 and checked whether this deacetylation of HDAC2 worked as an antihypertrophic mechanism. Hdac2 acetylation was significantly decreased by the forced overexpression of Hdac5 ( Figure 4G ). However, we did not observe the deacetylase effect of Hdac9 in our experimental models (Online Figure XIIC and XIID) .
Hdac2 acetylation was significantly increased in hearts from Hdac5-null mice ( Figure 5A ). Hdac5-null mice showed mild cardiac hypertrophy when compared with their wild-type littermates (data not shown), as described previously. 21 Like our previous observations in Figure 3A and 3C, Hdac2 phosphorylation was increased in Hdac5-knockout heart ( Figure 5A ). Hdac5 siRNA induced Hdac2 hyperacetylation ( Figure 5B ). Hdac2 activity was upregulated by siRNA against Hdac5 (Online Figure XIII) . Hdac2 acetylation was reduced when Hdac5 expression was elevated, which was completely reversed by simultaneous treatment with TSA ( Figure 5C ). Phosphorylation of Hdac2 S394 showed the same trend as the alteration of Hdac2 acetylation by Hdac5. As in Figure 2C , the enzyme activity of Hdac2 was significantly decreased by the forced expression of Hdac5, whereas the effect of Hdac5 on Hdac2 activity was successfully recovered by the inhibition of Hdac5 (Online Figure XIV) .
It is well known that the activity of class IIa HDACs is extremely lower than that of class I HDACs and that the recruitment of class I HDACs is required for the full activity of class IIa HDACs. 33 To elucidate whether HDAC5 is dependent on class I HDACs to deacetylase Hdac2, we checked deacetylation of Hdac2 in the presence of apicidin. Hdac2 acetylation was significantly decreased whether the cells were simultaneously treated with apicidin or not ( Figure 5D ). To support this result, we generated 2 enzyme-dead mutants of HDAC5 according to a previous report 34 and the bioinformatics site (http://www.uniprot.org/). One was a 767aa mutant 34 (lacking the HDAC domain) and the other was H833A (destruction of the HDAC pocket). We confirmed the intrinsic activity of HDAC5 mutants (Online Figure XV) . Hdac2 acetylation was decreased when wild-type HDAC5 was cotransfected (second and third lanes in Figure 5E) ; however, the enzyme-dead mutant of HDAC5 failed to show this effect (fourth and fifth lanes in Figure 5E) . These data strongly indicated that HDAC5 directly regulates HDAC2 acetylation.
Functional Relevance of Hdac2 Acetylation in Cardiac Hypertrophy
HDAC5 is phosphorylated by protein kinase C/D in response to various stimuli, including hypertrophy signals, and phosphor-HDAC5 undergoes nuclear export after recognition by the 14-3-3 molecule. 35 Leptomycin B (LMB), an antifungal antibiotic, inhibits the cytoplasmic shuttling of HDAC5 through direct binding to chromosomal region maintenance 1. 23 Thus, we used LMB to tether Hdac5 in the nucleus. When Hdac2 K75Q was infected to ARVCs, the LMB-mediated repressive effect of Hdac5 was not seen either in cell size measurement ( Figure 6A ) or in [ 3 H]leucine incorporation assay ( Figure 6B ). In addition, as in ARVCs, the LMB-mediated antihypertrophic effect was completely abolished by the simultaneous overexpression of Hdac2 K75Q in NRVCs ( Figure 6C ; Online Figure XVI) . Likewise, the overexpression of Hdac5 significantly reduced the activation of Nppa promoter by wild-type Hdac2; however, the antihypertrophic effect of forced expression of Hdac5 was not observed when Hdac2 K75Q was transfected ( Figure 6D) . Likewise, the exaggeration effect by Hdac5 siRNA was not observed in Hdac2 K75R-transfected NRVCs ( Figure 6E ). pCAF is also known as a putative prohypertrophic molecule. 36 We tested whether pCAF could induce cardiac hypertrophy, which is dependent on Hdac2 acetylation. The forced expression of pCAF in NRVCs induced cardiac hypertrophy, and the hypertrophic effect by pCAF was completely blocked when Hdac2 K75R was cotransfected ( Figure 6F ; Online Figure XVII ). Furthermore, we challenged whether Ad-Hdac2 K75R would function in a dominant-negative fashion in the development of cardiac hypertrophy in vivo. Isoproterenol-induced cardiac hypertrophy was significantly attenuated both in wild-type mice and Hdac5-null mice by the injection of Ad-Hdac2 K75R ( Figure 6G ). These results suggested that HDAC5 directly regulates HDAC2 activity by modulating the acetylation of HDAC2, which further implicates pCAF-dependent HDAC2 acetylation as a crucial step in the development of cardiac hypertrophy.
Discussion
Although initial hypertrophy is physiological, sustained stresses lead to a pathological phase of hypertrophy. When the heart undergoes transition into pathological hypertrophy, the myocardium becomes stiffened by interstitial fibrosis, and thereby diastolic dysfunction induces global remodeling of the heart, dilated cardiomyopathy, and heart failure. 37 We previously demonstrated that blocking class I HDACs effectively prevents the development of cardiac hypertrophy and that the activation of HDAC2 is associated with CK2α1-dependent HDAC2 S394 phosphorylation 19 and with binding of molecular chaperone, inducible heat shock protein 70. 26 Although both HDAC2 and class IIa HDACs are involved in cardiac hypertrophy, they play opposite roles. HDAC2 works as a prohypertrophic molecule, 18, 19, 26 whereas class IIa HDACs are negative regulators of cardiac hypertrophy. 21, 22 Considering Figure 5 . Hdac5 regulates Hdac2 activity by deacetylation. A, Both Hdac2 acetylation and S394 phosphorylation were increased in Hdac5-knockout (KO) mice. B, Hdac5 knockdown dramatically induced Hdac2 acetylation. C, Both Hdac2 acetylation and phosphorylation were significantly decreased by transient overexpression of Hdac5, which was completely reversed by trichostatin A (TSA). D, Hdac2 acetylation was successfully reduced by the overexpression of Hdac5, even when apicidin was added. E, Two enzymedead mutants, 767aa and H833A, failed to deacetylase Hdac2, whereas wild-type Hdac5 did.
the previous reports showing that the development of cardiac hypertrophy is completely blocked not only by a nonselective HDAC inhibitor but also by a class I HDAC-specific inhibitor, 17, 25 it is plausible that an interplay may exist between class I and class IIa HDACs in the regulation of cardiac hypertrophy and that class IIa HDACs directly regulate HDAC2 in an enzyme-substrate manner when cardiac hypertrophy develops.
In this study, we elucidated a novel regulation mechanism of HDAC2 acetylation in cardiac hypertrophy; pCAF-dependent HDAC2 K75 acetylation induces cardiac hypertrophy, which is closely linked to an increase in S394 phosphorylation induced by CK2α1. In contrast, HDAC5-mediated deacetylation of HDAC2 reduces the phosphorylation status and decreases the intrinsic activity of HDAC2. These results suggest that the acetylation dynamics of HDAC2 are also notable modification in addition to phosphorylation. Taken together, we suggest the working hypothesis depicted in Figure 7 ; in the basal state, HDAC5 binds to and suppresses HDAC2 by deacetylation (left). When hypertrophic insults stimulate the myocardium, phosphor-HDAC5 is redistributed to the cytoplasm as reported previously. 35 In HDAC5-free nucleus, HDAC2 is acetylated by pCAF and then phosphorylated by CK2α1, which allows HDAC2 to be activated. As a result, quiescent fetal genes are reactivated and cardiac hypertrophy develops (right). The most important finding of this study is the delineation of the new crosstalk mechanism in the regulation of cardiac hypertrophy; that is, HDAC2 is a direct target of class IIa HDACs. It is known that class II HDACs recruit class I HDACs to form a large complex and thereby repress the transcription of downstream targets. 33 However, in that case, it is not evident whether the acetylation status of HDACs in those complexes is altered by other histone acetyltransferases or HDACs. In contrast, in this study, we clearly show that HDAC5-mediated deacetylation of HDAC2 is critical in the regulation of the activity of HDAC2 in cardiomyocytes. HDAC9 also interacted with HDAC2; however, HDAC9 failed to deacetylate HDAC2. This finding also provides an alternative explanation as to how 2 opposite actions of prohypertrophic class I HDACs and antihypertrophic class IIa HDACs can work together in the regulation of cardiac hypertrophy.
The role of class II HDACs as enzymes in human disease is not as well understood as their role as transcriptional regulators owing to their lack of enzyme activities. 33 Indeed, their enzymatic activity does not seem to be directly associated with their antihypertrophic action. For example, MITR, an alternative splice form of HDAC9 that lacks a deacetylase domain, is still effective in preventing cardiac hypertrophy. 22 In this study, however, we demonstrated that LMB-dependent inhibition of nuclear export of HDAC5 completely suppresses the prohypertrophic effect of wild-type HDAC2, whereas an acetylation-mimicking mutant of HDAC2 is resistant to LMB. In addition to the previously known mechanism of transcriptional regulation by binding to other transcription factors, 22 our finding suggests that HDAC5 plays a role as a deacetylase enzyme targeting HDAC2, a novel nonhistone substrate. This eccentric relationship must be considered in the development of new HDAC inhibitors, because class IIa HDAC inhibitors may aggravate disease by the activation of prohypertrophic class I HDACs through their acetylation.
The functional importance of histone acetyltransferases in the development of cardiac hypertrophy is well established. Both p300 and pCAF successfully induce cardiac hypertrophy either by transcriptional activation of heart-specific genes 36 or by acetylation of nonhistone substrates such as GATA4. 38 In this study, in addition to these mechanisms, we demonstrated that pCAF, but not p300, induces acetylation and subsequent activation of HDAC2.
Studies of post-translational modifications of Hdac2 have intensively focused on phosphorylation. According to a study by the Seto group, 28 4 serine residues, S394, S411, S422, and S424, are susceptible to phosphorylation. Among them, S394, S422, and S424 are targets of CK2, and S411 is a target of protein kinase C. Moreover, CK2-dependent phosphorylation is essential for either intrinsic activity (S422/S424) 19, 28 or hypertrophy-associated transactivation (S394) 19 ; however, the ability of HDAC2 to repress transcription is not affected. 28 These reports suggest that the HDAC2-mediated hypertrophy response takes place not by the suppression of downstream genes but by the modulation of HDAC2's own nonhistone substrates.
In addition to HDAC2 phosphorylation, SUMOylation, 39 ubiquitylation, 40 S-nitrosylation, 30 and acetylation 41 are also reported. SUMOylation 39 and phosphorylation 42 regulate complex formation. Both DNA-binding affinity and the subsequent transcriptional inhibitory activity are affected by S-nitrosylation. 43 As shown in a chronic obstructive pulmonary disease model using cigarette smoke extract in lung epithelial cells and in macrophages, HDAC2 phosphorylation seems to be closely related to its acetylation. 41 Indeed, in our experimental model, HDAC2 phosphorylation-resistant mutants, S394A and S394/422/424A, and an enzyme activity-inert mutant, H141A, were successfully hyperacetylated. Whereas, their deacetylation activities were not upregulated by hyperacetylation in either phosphorylation-resistant mutants or the enzyme-dead mutant we investigated. These findings suggest that acetylation-associated increase in activity is not a direct effect but rather a secondary phenomenon by the modulation of interaction with kinase and thereby phosphorylation. Although we demonstrated that Hdac2 K75R fails to interact with CK2α1, it is still not clear how acetylation affects the binding of CK2 to HDAC2. Considering that acetylation causes conformational changes, 44 certain HDAC2 domains that are responsible for the interaction with CK2 might be exposed by K75 acetylation. Studies of post-translational modification and subsequent alterations of HDAC2 structure will provide a better understanding. In summary, our results suggest that the crosstalk between CK2-mediated phosphorylation and pCAF/HDAC5-induced acetylation plays a critical role in the development of cardiac hypertrophy by the regulation of HDAC2 activity. Such crosstalk requires further intensive investigations. Figure 7 . Working hypothesis. In the basal condition, HDAC5 inhibits HDAC2 by deacetylation (left). When hypertrophic stresses stimulate the myocardium, phosphor-HDAC5 is exported to the cytoplasm. Casein kinase 2α1 (CK2α1) is shuttled into the nucleus and phosphorylates HDAC2, and p300/ CBP-associated factor (pCAF) binds to HDAC2 and induces acetylation. Activated HDAC2 induces hypertrophy of the myocardium to satisfy the increased hemodynamic requirement (right). Ac indicates acetylation; and P, phosphorylation.
